Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 120Lymphoid 48Other hematologic neoplasm 47Myeloid 38Dermatologic 35Other neoplasm 27Sarcoma 17CNS 10Genitourinary 9Classical hematology 8Breast 7Gynecologic 6Gastrointestinal 4Thoracic 2Other solid neoplasm 1Other 1Head & Neck 1Endocrine 1

Conditions

Obesity 219Neoplasms 82Mucositis 66Sexual Dysfunction, Physiological 65Breast Neoplasms 64Polycystic Ovary Syndrome 56Overweight 55Dyspnea 32Motor Activity 30Constipation 30Head and Neck Neoplasms 28Prostatic Neoplasms 25Weight Loss 24Multiple Endocrine Neoplasia Type 1 19Colorectal Neoplasms 18Pain 16Diabetes Mellitus 16Stomatitis 15Lung Neoplasms 15Opioid-Induced Constipation 14Depression 14Cardiovascular Diseases 14Insulin Resistance 13Endometrial Neoplasms 13Sexuality 11Sexual Dysfunctions, Psychological 11Diabetes Mellitus, Type 2 11Fatigue 10Anxiety Disorders 10Stomach Neoplasms 8

Interventions

isatuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Immunoglobulin Light-chain Amyloidosis × Other × Clear all
NCT03499808 2025-09-09

S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis

SWOG Cancer Research Network

Phase 2 Completed
43 enrolled 23 charts
GastrointestinalOtherPlasma cell

Lymphadenopathy, Immunoglobulin Light-chain Amyloidosis, Constipation, Diarrhea, Gastrointestinal Hemorrhage, Hepatomegaly, Macroglossia, Nausea, Purpura

Data powered by HemOnc (CC BY 4.0) Colophon âš¡